Status:

COMPLETED

Study of a Novel Technique of Mechanical Ventilation in Patients With Severe Acute Respiratory Failure

Lead Sponsor:

University of Athens

Collaborating Sponsors:

University of Thessaly

Conditions:

Respiratory Distress Syndrome

Eligibility:

All Genders

18-75 years

Phase:

PHASE2

PHASE3

Brief Summary

The investigators have recently demonstrated the beneficial effects of combined high-frequency oscillation (HFO) and tracheal gas insufflation (TGI) on the respiratory physiology \[1,2\] of patients w...

Detailed Description

BACKGROUND AND OBJECTIVES The prognosis of ARDS still remains grave \[3-7\]. The primary objective of the present study, is to definitively determine the effect of HFO-TGI on the survival of patients...

Eligibility Criteria

Inclusion

  • Age 18-75 years
  • Body weight \> 40 kg
  • Endotracheal intubation and mechanical ventilation
  • Diagnosis of ARDS established within preceding 72 h
  • Severe oxygenation disturbances: PaO2/FiO2 \<150 mm Hg sustained for 12 h, despite being ventilated with PEEP ≥8 cm H2O

Exclusion

  • Active air leak or recent severe air leak (severe air leak: \> 1 chest tube per hemithorax with persistent gas leak for \> 72 h)
  • Severe hemodynamic instability (i.e., systolic arterial pressure \< 90 mm Hg despite volume loading and norepinephrine infusion at ≥ 0.5 μg/kg/min)
  • Significant heart disease (i.e., ejection fraction \<40 %, and/or history of pulmonary edema, and/or active coronary ischemia or myocardial infarction)
  • Significant chronic obstructive pulmonary disease (COPD) or asthma {i.e., previous admissions for COPD/asthma, chronic corticosteroid therapy for COPD/asthma, and documented chronic CO2 retention leading to a baseline PaCO2 of \> 50 mm Hg (for COPD)}
  • Uncontrollable intracranial hypertension (i.e., intracranial pressure \>20 mm Hg despite deep sedation, analgesia, hyperosmolar therapy, and minute ventilation titrated to PaCO2 = 35 mm Hg)
  • Chronic Interstitial Lung Disease associated with bilateral pulmonary infiltrates
  • Lung biopsy or resection on current admission
  • Immunosuppression caused by
  • neutropenia \[i.e., polymorphonuclear leukocyte count \< 1,000/μL (1 x 1012/L)\] after chemotherapy or bone marrow transplantation for hematologic cancers
  • corticosteroid or cytotoxic therapy for a nonmalignant disease
  • the acquired immunodeficiency syndrome
  • Inability to wean from prone positioning or inhaled nitric oxide
  • Pregnancy or morbid obesity (body mass index \>40 kg/m2)
  • Enrollment in another interventional study
  • Crossover from the CMV-group to the HFO-TGI-group at \> 72 h after the onset of the severe oxygenation disturbances

Key Trial Info

Start Date :

March 1 2008

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

May 1 2009

Estimated Enrollment :

124 Patients enrolled

Trial Details

Trial ID

NCT00637507

Start Date

March 1 2008

End Date

May 1 2009

Last Update

November 21 2016

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

Department of Intensive Care Medicine, Evaggelismos Hospital

Athens, Attica, Greece, GR-10675

2

University General Hospital of Larissa

Larissa, Thessaly, Greece, GR-41110